Ensysce Biosciences
ENSCENSC · Stock Price
Historical price data
Overview
Ensysce Biosciences is developing transformative, prodrug-based technologies to address the prescription opioid epidemic by preventing both abuse and overdose. Its core platforms, TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance), represent a paradigm shift from physical barrier formulations to intrinsic chemical control of drug activation. The company has achieved significant regulatory momentum with Fast Track and Breakthrough Therapy designations for its lead opioid candidates and is advancing clinical trials. Ensysce's strategy is to create safer pain therapies and potentially apply its chemistry to other drug classes with high abuse potential.
Technology Platform
Two proprietary prodrug platforms: TAAP™ (Trypsin-Activated Abuse Protection) for tamper-resistance and MPAR® (Multi-Pill Abuse Resistance) for overdose protection, which together control drug activation via a unique chemical mechanism in the gut.
Pipeline
9| Drug | Indication | Stage | Watch |
|---|---|---|---|
| PF614 capsule + Placebo | Postoperative Pain, Acute | Phase 3 | |
| PF614 + Placebo | Acute Pain | Phase 2 | |
| PF614 + Oxycodone | Recreational Drug Use | Phase 1 | |
| PF614 + Naltrexone Hydrochloride + OxyContin | Healthy Volunteers | Phase 1 | |
| PF614 + Oxycodone extended-release + Naltrexone Hydrochlorid... | Healthy | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Ensysce competes with makers of physical barrier-type Abuse-Deterrent Formulation (ADF) opioids (e.g., OxyContin, Xtampza ER). Its key differentiation is the combination of abuse-deterrence (TAAP™) with a novel pharmacological approach to overdose protection (MPAR®), a feature no marketed product possesses. Success hinges on proving clinical superiority over these established ADFs.
